Serum levels of macular carotenoids in relation to age-related maculopathy

Dasch, Burkhard; Fuhs, Andrea; Schmidt, Jan Peter; Behrens, Thomas; Meister, Astrid; Wellmann, Juergen; Fobker, Manfred; Pauleikhoff, Daniel; Hense, Hans‐Werner

doi:10.1007/s00417-005-1176-z

Cited by 38 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From June 2001 to October 2003, a cohort of 1060 individuals from the city of Muenster and the surrounding counties was assembled. [32][33][34] All participants were of Caucasian origin. A cross-sectional analysis of this baseline examination is the basis of the present report.…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study

Farwick

Dasch

Weber

et al. 2009

Eye

View full text Add to dashboard Cite

Aims Little is known about the role of genetic variants in the early stages of age-related macular degeneration (AMD). We aimed to investigate how genetic variations within five well-defined genes relate to AMD severity. Methods We analysed SNPs in the genes for complement factor H (CFH), age-related maculopathy susceptibility (ARMS2), HtrA serine peptidase 1 (HtrA1), complement factor B (CFB), and complement component 2 (C2) in 183 controls and 730 patients with increasing severity of AMD from the Muenster aging and retina study (MARS). Severity scoring was based on the Rotterdam classification of fundus photographs. Results Compared with controls, patients with very early AMD showed a significantly increased minor allele frequency (MAF) only for CFH-rs1061170. With increasing severity of AMD, SNPs in CFH-rs1061170, as well as ARMS2-rs10490924, became consistently more common (Po0.001). Likewise, HtrA1-rs11200638 was less clearly associated with AMD severity, whereas C2-rs9332739 and CFB-rs641153 showed no relation. Multifactorial models confirmed CFH and ARMS2 as major determinants of AMD severity, whereas addition of HtrA1, C2 and CFB did not improve model prediction. In the models, age did not contribute to very early but to all more severe AMD stages, whereas smoking history had a significant impact only for late AMD. ConclusionOur findings indicate that the CFH gene is involved in the onset of AMD, whereas both, the CFH and ARMS2 genes, and more weakly, the HtrA1 gene, appear to account for the advancement of AMD. The results for SNPs in the C2 and CFB genes were inconclusive. Genetic factors dominated in their impact over age and smoking history.

show abstract

Section: Study Populationmentioning

confidence: 99%

“…32 All digital images were evaluated on a 22-inch computer screen by specially trained technicians. The presence and severity of retinal lesions were graded according to the protocol of the International age-related maculopathy (ARM) Epidemiological Study Group.…”

Section: Examination Procedures and Fundus Photographymentioning

confidence: 99%

Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study

Farwick

Dasch

Weber

et al. 2009

Eye

View full text Add to dashboard Cite

show abstract

“…Although some epidemiological studies have found an inverse correlation between dietary intake and/or serum concentrations of lutein-zeaxanthin and the risk of AMD [16,17,18,19,20,21], a number of investigations have failed to observe this correlation [22,23,24,25,26,27,28]. The largest randomized controlled trial (RCT) in this area so far with a median follow-up of 5 years, the Age-Related Eye Disease Study 2 (AREDS2), evaluated the roles of lutein-zeaxanthin, docosahexaenoic acid (DHA)-eicosapentaenoic acid combinations and a combination of both these formulations, but found no reduction in the risk of AMD progression in any group in a sample of 4,203 participants at risk of progression to advanced AMD [29,30].…”

Section: Introductionmentioning

confidence: 99%

Role of Lutein Supplementation in the Management of Age-Related Macular Degeneration: Meta-Analysis of Randomized Controlled Trials

et al. 2014

View full text Add to dashboard Cite

Objective: The conduct of this meta-analysis aimed at examining the individual role of lutein as a dietary supplement in improving conditions of age-related macular degeneration (AMD) from the data generated from randomized controlled trials (RCTs). Method: The literature search was made in multiple electronic databases. Eligibility criteria were RCTs that recruited AMD patients or individuals at risk and evaluated lutein supplementation efficacy against placebo. The quality of the trials was assessed by using the Jadad scale. The meta-analysis was conducted under the fixed effect model with RevMan software by calculating the mean differences of the changes from baseline of both lutein and placebo groups. Parameters of interest were macular pigment optical density (MPOD) and visual acuity (VA) in logMAR (minimum angle of resolution). Heterogeneity was determined by χ² and I² and publication bias was assessed by visual examination of funnel plots. Results: After following predetermined inclusion and exclusion criteria, five RCTs that recruited 445 participants were selected for the meta-analysis. It has been found that lutein treatment was associated with a significant improvement in MPOD, with mean differences between lutein and placebo groups in the changes from baseline of 0.09 (95% CI: 0.06, 0.12; p < 0.00001). VA also improved with a mean difference between lutein and placebo groups in the changes from baseline of −0.04 (95% CI−0.07, 0.00; p = 0.05). Statistical heterogeneity was not apparent. Conclusion: A statistically highly significant effect of lutein supplementation has been observed for improving the MPOD, whereas the improvement in VA was milder. A daily dose of 10 mg was found as effective as higher doses in this meta-analysis. However, the number of input studies is not adequate for conclusive evidence.

show abstract

“…Nevertheless, and with full appreciation of the limitations of associative studies, there have been no less than 12 cross-sectional reports attempting to investigate the relationship between serum concentrations of macular pigment's constituent carotenoids and the risk for AMD (see Table 2). [20][21][22][23][33][34][35][36][37][38][39][40] Further, and notwithstanding the fact that many of these cross-sectional studies were performed in the pre-AREDS 2 era, it should be appreciated that lutein-containing supplements were commercially available since 1999, 41 and since that date their use grew substantially as a result of widespread dissemination of their putative benefits. [42][43][44][45][46][47][48] Meaningful comment on any such relationship should be predicated, therefore, on population-based studies where data were recorded pre-1999 and to subsequent population-based studies where the use of carotenoid-containing supplements was recorded and appropriately factored into analyses.…”

mentioning

confidence: 99%

The Relationship Between Plasma Concentrations of Lutein and Zeaxanthin with Self-Reported and Actual Prevalence of AMD in an Irish Population-Based Sample

Moran

Beatty

Stack

et al. 2017

Current Eye Research

View full text Add to dashboard Cite

Purpose: To investigate plasma lutein (L) and zeaxanthin (Z) concentrations with grading-confirmed and self-reported prevalence of age-related macular degeneration (AMD). Material and methods: Data collected from a nationally representative prospective cohort study of community-dwelling adults aged 50 years and over in the Republic of Ireland. Participants underwent a computer-assisted personal interview and a center-based health assessment. Plasma concentrations of L and total Z (Z and meso-zeaxanthin [MZ]) were measured by high performance liquid chromatography, and retinal photographs were graded using a version of the AMD International Classification and Grading System. Consumption of supplements containing L and/or Z and/or MZ was recorded as supplement use. Four groups were identified: Group 1 (n = 24): AMD-afflicted and correctly aware; Group 2 (n = 264): AMD-afflicted but unaware; Group 3 (n = 41): AMD-free and incorrectly believed that they were afflicted with the condition; Group 4 (n = 4094): AMD-free and correctly self-reported absence of AMD. Results: Of 4,423 participants with plasma concentrations of L and Z and gradable retinal photographs, 288 (6.5%) were afflicted with AMD, and 65 (1.5%) self-reported AMD. Controlling for family history and age, the relationship between grading-confirmed AMD and plasma L was positive and significant (p < 0.001). Mean plasma concentrations of L in Group 2 (mean = 0.2162 ± 0.132 µmol) and Group 4 (mean = 0.2040 ± 0.121 µmol/L) were significantly lower than Group 1 (mean = 0.4691 ± 0.0.372 µmol/L) and Group 3 (mean = 0.3176 ± 0.0.235 µmol/L). Supplement use was reported by 41.7% and 17.1% of participants in Groups 1 and 3, respectively, but only 2.7% and 1.9% of participants in Groups 2 and 4, respectively. Conclusion: A belief that one suffers from AMD, whether justified or not, is associated with supplement use and with higher plasma concentrations of L. ARTICLE HISTORY

show abstract

Serum levels of macular carotenoids in relation to age-related maculopathy

Abstract: In this large study, the serum concentrations of L and Z were not related to the prevalence of ARM. However, the large proportion of study participants taking L and/or Z supplementation may have affected these results.

Cited by 38 publications

References 44 publications

Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study

Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study

Role of Lutein Supplementation in the Management of Age-Related Macular Degeneration: Meta-Analysis of Randomized Controlled Trials

The Relationship Between Plasma Concentrations of Lutein and Zeaxanthin with Self-Reported and Actual Prevalence of AMD in an Irish Population-Based Sample

Contact Info

Product

Resources

About